Enclomiphene Citrate Sexual Function Impact: What the Clinical Evidence Shows

Does enclomiphene improve libido or erectile function?

The phase 3 trials reported hormones and semen, not sexual function. On 25 January 2018 the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion recommending refusal of authorisation for EnCyzix (enclomifene), and said the studies showed higher testosterone but did not examine whether symptoms improved: bone strength, weight gain, impotence, libido. The application rested on four main studies in 588 patients [1].

FDA has made the wider point for secondary hypogonadism. Its 2018 guidance, as FDA described it in 2022, says it is unclear whether raising testosterone in this population gives clinical benefit, that trials should show meaningful improvement in at least one symptom or sign, and that semen-parameter changes alone are not enough to establish efficacy [2].

The phase 3 enclomiphene programme measured testosterone, LH, FSH and sperm counts. It did not measure symptom or quality-of-life improvement, a gap both FDA and EMA identified [2].

Enclomiphene raises testosterone, and testosterone is what the trials set out to normalise, so any effect on libido or erections would be indirect and is not established by these studies.

What the trials showed about testosterone

Enclomiphene is an oral selective estrogen receptor modulator. It blocks estrogen receptors in the pituitary, where estrogen normally suppresses the pituitary-testis axis, so the pituitary releases more LH and FSH and the testes make more testosterone [2]. That applies to secondary (hypogonadotropic) hypogonadism, where the testes are healthy but under-stimulated; in primary hypogonadism, where the testes themselves have failed, it would not be expected to work [2].

A randomized phase 2 study enrolled 48 men and tested enclomiphene doses of 6.25, 12.5 and 25 mg daily for six weeks against transdermal testosterone gel; testosterone and LH rose with enclomiphene [6]. A second phase 2 trial found enclomiphene raised morning testosterone, estradiol and LH to levels similar to 1% testosterone gel [8].

Two 12-week phase 3 studies reported 78.8% of pooled enclomiphene patients (95% CI 70.3 to 85.3, n=113) reaching an average 24-hour testosterone of 300 to 1040 ng/dL in ZA-301 (151 men) [7], and 81.3% (95% CI 73.9 to 87.0, n=134) in ZA-302 (181 men) [5]. Both results are ClinicalTrials.gov postings.

A 2025 meta-analysis of randomized SERM trials in men with functional hypogonadism, with clomiphene and enclomiphene pooled, found total testosterone higher than placebo by a mean 273.76 ng/dL (95% CI 191.87 to 355.66), with high heterogeneity (I2 89%), and no significant difference in testosterone versus testosterone gel [3]. The analysis does not separate the two drugs.

Sperm: the difference the trials did capture

The clearest documented difference between enclomiphene and testosterone therapy is in semen. Two parallel randomized, double-blind, double-dummy, placebo-controlled phase 3 studies (ZA-304 and ZA-305, BJU International 2016) compared two doses of enclomiphene with AndroGel 1.62% for 16 weeks in overweight men aged 18 to 60 with morning testosterone of 300 ng/dL or lower. Total testosterone rose in all treatment groups. LH and FSH rose with enclomiphene and fell with testosterone gel. Sperm concentration stayed in the normal range on enclomiphene, while there was a marked reduction in spermatogenesis on the gel [4]. The published summary gives no numerical sperm figures.

Preservation is not universal. Sperm concentration fell by 50% or more in 14.2% of men on enclomiphene versus 2.6% on placebo in ZA-301 [7], and in 14.2% versus 4.3% in ZA-302 [5].

In a 12-man phase 2b study of men previously using topical testosterone, sperm counts rose in 7 of 7 men on enclomiphene at three months, while the gel raised counts above 20 million/mL in none of 5 men at three months; testosterone returned to pre-treatment values one month after enclomiphene stopped [9].

For comparison, exogenous testosterone can disrupt the hypothalamic-pituitary-gonadal axis and impair spermatogenesis, with azoospermia a possible result [10].

Side effects and safety concerns

The most frequent side effects in the phase 3 and EMA data were headache, hot flushes, nausea and muscle spasm; stopping reasons included blurred vision, muscle spasm, headache and aggression. In ZA-302, headache was reported by 7 of 112 men on 12.5 mg versus 1 of 47 on placebo, and nausea by 4 of 112 versus 3 of 47 [5].

FDA's 2022 review listed safety concerns from published trials, adverse event reports and EMA's review: cardiac and thromboembolic events including pulmonary embolism and deep vein thrombosis in a safety study, raised estradiol, raised PSA, raised hematocrit, and no long-term safety data [2]. EMA noted a slightly higher rate of cardiac and thromboembolic events than with testosterone, and wanted ocular monitoring after cataracts appeared in nonclinical studies [2].

In a retrospective single-center study of 66 men who took clomiphene and later enclomiphene, the median estradiol change was -5.92 pg/mL on enclomiphene versus +17.50 pg/mL on clomiphene (P=0.001) [11].

No FDA-approved drug contains enclomiphene as an active ingredient, so the clomiphene citrate label should not be treated as an enclomiphene-specific label [2][12]. That label covers the mixture, not enclomiphene alone. It warns of visual symptoms such as blurring, spots, flashes and scotomata that are usually reversible but may rarely persist [12]. It also notes that gynecomastia and testicular tumors have been reported in men using clomiphene, with cause and effect not known [12]. These warnings are for clomiphene citrate and are not proven to apply to enclomiphene alone [12].

Approval status and what is available

No FDA-approved drug contains enclomiphene as an active ingredient [2]. In 2015 the sponsor, Repros Therapeutics, announced a complete response letter from FDA; as FDA summarized it, the design of the phase 3 studies was not adequate to demonstrate clinical benefit, and there were concerns about entry criteria, titration and bioanalytical method validation [2]. EMA's committee adopted a negative opinion on 25 January 2018 [1]. A 2026 British Society of Sexual Medicine position statement notes the manufacturer discontinued development in 2021 and advises use only by experienced clinicians in specialist or research settings, because long-term efficacy and safety data are lacking [13].

Clomiphene citrate is a mixture of enclomiphene (trans) and zuclomiphene (cis); the USP monograph gives an enclomiphene content of 50 to 70 percent [2]. Clomiphene is FDA-approved only for ovulatory dysfunction in women who want to become pregnant, its label has no male indication, and it states that there are no adequate or well-controlled studies demonstrating effectiveness in male infertility [12].

On compounding, enclomiphene citrate is in FDA's Category 1, Bulk Drug Substances Under Evaluation (list updated 14 May 2026). FDA says it does not intend to take action against a compounder using a Category 1 substance if the conditions in its guidance are met; that is an enforcement-discretion policy, not an approval and not a finding that the product is safe or effective [14]. Compounded enclomiphene products are not FDA-approved and have not been reviewed by FDA for safety, effectiveness or quality [16].

HealthRX.com offers enclomiphene by prescription.